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Therapies to prevent transmission of malaria parasites to the mosquito vector are a vital part of the global malaria elimination
agenda. Primaquine is currently the only drug with such activity; however, its use is limited by side effects. The development of
transmission-blocking strategies requires an understanding of sexual stage malaria parasite (gametocyte) biology and the identi-
fication of new drug leads. Lysine acetylation is an important posttranslational modification involved in regulating eukaryotic
gene expression and other essential processes. Interfering with this process with histone deacetylase (HDAC) inhibitors is a vali-
dated strategy for cancer and other diseases, including asexual stage malaria parasites. Here we confirm the expression of at least
one HDAC protein in Plasmodium falciparum gametocytes and show that histone and nonhistone protein acetylation occurs in
this life cycle stage. The activity of the canonical HDAC inhibitors trichostatin A (TSA) and suberoylanilide hydroxamic acid
(SAHA; Vorinostat) and a panel of novel HDAC inhibitors on early/late-stage gametocytes and on gamete formation was exam-
ined. Several compounds displayed early/late-stage gametocytocidal activity, with TSA being the most potent (50% inhibitory
concentration, 70 to 90 nM). In contrast, no inhibitory activity was observed in P. falciparum gametocyte exflagellation experi-
ments. Gametocytocidal HDAC inhibitors caused hyperacetylation of gametocyte histones, consistent with a mode of action tar-
geting HDAC activity. Our data identify HDAC inhibitors as being among a limited number of compounds that target both asex-
ual and sexual stage malaria parasites, making them a potential new starting point for gametocytocidal drug leads and valuable
tools for dissecting gametocyte biology.
Malaria remains a significant infectious disease, resulting inhundreds of millions of clinical cases and an estimated 0.8
million to 1.2 million deaths annually (1). The lack of a licensed
malaria vaccine and the increasing incidence of parasite resistance
to current drugs (2, 3) exacerbate the global burden ofmalaria and
hinder efforts to eliminate this disease. Most current antimalarial
drugs target intraerythrocytic asexual stage parasites, which are
responsible for the clinical symptoms of malaria. Although the
development of new drugs that target the asexual blood stage re-
mains a high priority, the elimination of malaria also requires the
development of drugs to target other key life cycle stages, includ-
ing preerythrocytic (liver) and gametocyte stages. Targeting of
preerythrocytic stage parasites has the potential for true causal
prophylaxis, while targeting of gametocytes may block parasite
transmission. Plasmodium gametocytes are the sexual stage of
the malaria parasite that develops in red blood cells and can be
transmitted directly from the mammalian host to the female
Anophelinemosquito vector during a bloodmeal. Gametocytemia
can persist for 2 to 8 weeks after asexual infection is cleared (4),
depending on the drug used, allowing parasite transmission to
continue. There are currently no licensed antimalarial drugs with
a demonstrated ability in a clinical setting to kill or inhibit game-
tocytes that are safe for communitywide use. The only clinically
used drug that can eliminate mature gametocytes, primaquine, is
contraindicated for people with severe glucose-6-phosphate de-
hydrogenase (G6PD) deficiency. In these patients, primaquine
treatment has the potential to result in hemolytic anemia. Prima-
quine is also considered unsafe during pregnancy, as the G6PD
status of the fetus is not known.
During Plasmodium falciparum infection, gametocytes gener-
ally appear at about 10 to 14 days after the first appearance of
asexual stage parasites in the host bloodstream. Gametocytogen-
esis, the process leading to the development of gametocytes from
asexual stage parasites, represents a transition period during
which time the parasite differentiates morphologically and bio-
chemically. This maturation process can be divided into five dis-
tinct stages (stages I to V) on the basis of light and electron mi-
croscopy (5). Stage I and early stage II parasites are almost
indistinguishable from asexual stage parasites. Parasites commit-
ted to sexual development become morphologically distinguish-
able only at late stage II and stage III, about 72 to 96 h after inva-
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sion of a committed asexual stage merozoite into an erythrocyte.
As the gametocytematures, it transitions through stage IV to stage
V, where parasites have a characteristic crescent shape. Upon in-
gestion by a mosquito, male gamete formation occurs rapidly
(20 min) and is induced by a decrease in temperature and the
mosquito-derived gametocyte-activating factor xanthurenic acid
(6). This process involves three rounds of DNA replication and
axoneme assembly, resulting in the release of up to eight gametes
per male gametocyte (7, 8). In contrast, female gametocytes hold
370 gene transcripts in translational repression (controlled by
DOZI) until gamete formation, egress from the red blood cell, and
fertilization (9).
The process of gametocytogenesis involves numerous genetic
andmetabolic changes that are not fully understood, but it is clear
that these changes impact drug efficacy. Asexual blood and early
gametocyte stages (stages I to III) have similar metabolic profiles,
and consequently, many drugs are assumed to be active against
both of these forms, although recent work suggests that there may
be fewer cross-efficacious drugs than was first thought (10). In
contrast, mature (stage IV and V) gametocytes have been thought
to be relatively less metabolically active than asexual stage para-
sites and, with the exception of primaquine, have been considered
insensitive to currently used antimalarial drugs. However, recent
work has shown that rather than being largely quiescent in regard
to their metabolic activities, gametocyte development is associ-
ated with more metabolic changes than was previously thought
(11). This suggests that mature gametocytes do turn on the differ-
ent proteins and pathways needed for rapid development into
gametes. During gametocytogenesis and transmission, P. falcipa-
rum parasites express new sets of genes and proteins likely to be
important for sexual development, survival, and reproduction in
the mosquito vector (12–19). For example, gametocyte matura-
tion and gametocytogenesis are accompanied by the coordinated
expression of adhesive proteins, such as the epidermal growth
factor domain-containing proteins P. falciparum s25 (Pfs25) and
P. falciparum s28 (Pfs28), the 6-Cys proteins P. falciparum s230
(Pfs230) and P. falciparum s48/45 (Pfs48/45), and the LCCL do-
main-containing P. falciparum CCp (PfCCp) proteins (20–23).
Recent work has also identified the P. falciparum gametocyte de-
velopment 1 (Pfgdv1) gene as being critical for gametocyte pro-
duction (24). In addition, transcriptomic data demonstrate signif-
icant changes in a subset of genes immediately following malaria
parasite transmission to the mosquito (17).
Radical changes in gene expression in response to different
morphological states and environments is well documented for
asexual blood-stage parasites, where epigenetic control is thought
to contribute to the regulation of gene expression across the intra-
erythrocytic developmental cycle by maintaining Plasmodium
genomic hetero- and euchromatin domains (25–29). Although no
studies have yet been carried out on epigenetic control during
gametocyte development, the observed changes in gene transcrip-
tion and protein expression suggest a role for epigenetic control of
gene expression during this life stage. This prompted us to inves-
tigate the effect of known chemical epigenetic modifiers, namely,
histone (also called lysine) deacetylase (HDAC) inhibitors, on ga-
metocytes with a view to identifying novel tools to study gameto-
cyte development and new transmission-blocking approaches.
HDACs are validated drug targets for asexual stage P. falciparum
parasites (reviewed in reference 30), with potent antimalarial
HDAC inhibitors causing alterations in global histone acetylation
profiles and perturbing transcriptional control in asexual blood-
stage parasites, causing both up- and downregulation of sets of
genes (31–33). Little is known about Plasmodium HDACs in the
sexual stage of reproduction of malarial parasites.
MATERIALS AND METHODS
Compounds used in this study. Suberoylanilide hydroxamic acid
(SAHA; Sigma-Aldrich) was prepared as 10 to 200 mM stock solutions in
100% dimethyl sulfoxide (DMSO). N-[4-[3-[[[7-(Hydroxyamino)-7-
oxoheptyl]amino]carbonyl]-5-isoxazolyl]phenyl]-1,1-dimethylethyl-
ester and carbamic acid (CAY10603; Cayman Chemicals) were prepared
as 10 mM stock solutions in 100% DMSO. Trichostatin A (TSA; Sigma-
Aldrich) and chloroquine (chloroquine diphosphate salt; Sigma-Aldrich)
were prepared as 10 to 50 mM stocks in ethanol and Milli-Q ultrapure
water, respectively. Tosyllysine chloromethyl ketone hydrochloride
(TLCK; Sigma-Aldrich) was prepared as a 3 mM stock in methanol. De-
tails of chemical synthesis, including synthetic schemes, of hydroxamate-
basedHDAC inhibitors 1 to 5 (see Fig. 3 for structures) can be found in the
supplemental material.
P. falciparum culture and gametocyte preparation. Asexual stage P.
falciparum drug-sensitive (line 3D7 [34]) and drug-resistant (line Dd2
[35]) parasites were cultured in type O-positive human erythrocytes in
RPMI 1640 medium (Life Technologies) supplemented with 10% heat-
inactivated human serum and 50mg/liter hypoxanthine, using amodified
method of Trager and Jensen (1976) (36). Parasites were synchronized by
sorbitol treatment, as previously described (37). Gametocytes were ob-
tained using a modification of a published protocol (38) (method 1).
Briefly, cultures of synchronous 3D7c (39) ring-stage parasites at 2 to 3%
parasitemia were cultured through one invasion cycle to achieve a para-
sitemia of 6 to 8%. Following treatment with 5% sorbitol (37) to synchro-
nize for ring stages, parasites were cultured until they reached the tropho-
zoite stage and then diluted to 2% parasitemia and 5% hematocrit with
fresh uninfected human erythrocytes. Following reinvasion to the ring
stage (termedmethod 1, day 0 [M1-d0]), cultures weremaintained under
standard conditionswith a dailymedium change but without the addition
of fresh erythrocytes. Daily medium changes included 5% sorbitol (40) or
50 mM N-acetylglucosamine (NAG) (41) to remove asexual stage para-
sites. Gametocyte maturation was monitored daily by microscopic exam-
ination of Giemsa-stained thin blood smears.
P. falciparum culture and gametocyte preparation for early and late
stage gametocyte imaging-based viability assays. P. falciparum NF54
parasites expressing the gametocyte-specific protein s16 (Pfs16) fused to
green fluorescent protein (GFP) (NF54Pfs16-GFP) were cultured and in-
duced as described previously (42) (method 2). Briefly, sorbitol-synchro-
nized asexual stage parasites were cultured at low parasitemia, and tro-
phozoites were isolated on magnetically activated cell sorting (MACS)
columns at day3. The hematocrit was dropped from5% to 1.25%. After
overnight incubation, ring-stage parasites (10 to 15% parasitemia; day
2) received three parts freshmedium (with one part spent/usedmedium
not being replaced) and were then left to develop into gametocyte-com-
mitted or noncommitted trophozoites through an overnight incubation.
The day1 trophozoite parasitemia was reduced to 3%, and the culture
was incubated overnight. On day 0 (termed method 2, day 0 (M2-d0),
young ring-stage parasites and spontaneously generated gametocytes
were observed. Spontaneously generated gametocytes were removed from
the ring-stage culture using MACS columns. For use in the early-stage
(stage I to III) MitoTracker Red CM-H2XRos imaging-based viability as-
say, parasitemia was reduced to 4% rings at 2.5% hematocrit, the culture
was incubated overnight, and medium was replaced (day 1) before a fur-
ther 24 h incubation. On day 2, early gametocytes were isolated from
asexual ring-stage parasites using MACS columns. Day 0 parasites were
also cultured inmedium containing 50mMNAG,withmedium exchange
being performed daily up to day 8 for use in the MitoTracker Red
CM-H2XRos late-stage (stage IV and V) gametocyte imaging-based via-
bility assay.
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Diagnostic RT-PCR.Total RNAwas isolated from trophozoites of the
non-gametocyte-producing strain F12 and different stages of the gameto-
cyte-producing strain NF54 using the TRIzol reagent (Invitrogen), ac-
cording to the manufacturer’s protocol. Stages isolated from the NF54
strain included enriched immature stage III gametocytes, nonactivated
stage V gametocytes, and stage V gametocytes following 30min activation
with 100 M xanthurenic acid. RNA preparations were treated with
RNase-free DNase I (Qiagen) to remove genomic DNA contamination,
followed by phenol-chloroform extraction and ethanol precipitation.
cDNA synthesis was carried out using a SuperScript III first-strand syn-
thesis system (Invitrogen), following the manufacturer’s instructions.
PCR was performed using the following conditions: initial denaturation
at 94°C for 2min, followed by 25 cycles of 94°C for 30 s, annealing at 55°C
for 30 s, and 72°C for 30 s and a final extension at 72°C for 1min. The stage
specificity of the RNA samples was verified by monitoring transcripts of
two stage-specific markers: P. falciparum apical membrane antigen 1
(PfAMA1) of asexual blood stages and the gametocyte-specific LCCL do-
main-containing protein PfCCp2. Controls without reverse transcriptase
(RT) were included to ensure that the samples were not contaminated
with genomic DNA. PCR products were analyzed by agarose gel electro-
phoresis. The transcript of the ubiquitousmetabolic protein P. falciparum
fructose-1,6-bisphosphate aldolase (PfAldo) was used as a loading con-
trol. The primers used for diagnostic RT-PCR are shown inTable S1 in the
supplemental material.
Immunofluorescence assay.Mature stageV 3D7c gametocytes (method
1) were cultured as described above and washed 3 times with RPMI 1640
medium (Life Technologies), and thin blood films were prepared on glass
microscope slides. Slides were fixed with ice-cold 90% acetone–10%
methanol and then probed using an anti-P. falciparum HDAC1 (anti-
PfHDAC1) polyclonal rabbit antibody in 3% bovine serum albumin (Bo-
vogen). These antisera were raised (IVMS, South Australia. Australia)
against a C-terminal peptide of PfHDAC1 (PlasmoDB gene accession num-
ber PF3D7_0925700) with a previously published amino acid sequence
(43). Specificity was confirmed via Western blotting against recombinant
PfHDAC1 (Sigma-Aldrich) (data not shown). Following washing to remove
unbound primary antibody, slides were incubatedwith goat anti-rabbit IgG-
Cy2 (Jackson) and Hoechst 33258 dye (Sigma-Aldrich) to stain the nuclei.
Cellswere visualized on anAppliedPrecisionDeltaVisiondeconvolutionmi-
croscope. Prebleed and secondary antibody-only controls were also included
to ensure that the signal was specific.
Analysis of gametocyte lysine acetylationprofiles.Gametocyteswere
generated from synchronous P. falciparum 3D7c asexual stage parasite
cultures as described above (method 1), and samples were collected on
days 4, 6, 8, and 10 relative to the start of induction (M1-d0). Protein
lysates were prepared by pelleting the cells by centrifugation, lysing with
0.15% saponin (Sigma-Aldrich), and then washing extensively using
phosphate-buffered saline (PBS; pH 7.4) to remove hemoglobin. Parasite
pellets were then resuspended in 1 SDS-PAGE loading dye, heat dena-
tured at 96°C for 3 min, and then separated via SDS-PAGE (5  106
parasite equivalents per lane). For analysis of low-molecular-mass
(25-kDa) histone proteins, 15%SDS-PAGEwas used. For nonhistone
protein analysis, 10% SDS-PAGE was used to allow separation and anal-
ysis of proteins of25 kDa. Protein was transferred to a polyvinylidene
difluoride (PVDF) membrane (Roche), andWestern blotting was carried
out using Odyssey blocking buffer (LI-CORBiosciences) according to the
manufacturer’s instructions. Anti-pan-acetyl lysine (K103) monoclonal
primary antiserum (Cell Signaling Technology) was used with goat anti-
rabbit IRDye secondary antisera (LI-COR Biosciences) to detect changes
in nonhistone protein acetylation. Anti-tetra-acetylated (lysines 5, 8, 12,
and 16) H4 histone primary antibody (Millipore) was used with goat
anti-rabbit IRDye secondary antibody (LI-COR Biosciences) to detect
changes in histone H4 acetylation. Antisera recognizing Pfs16 and P. fal-
ciparum glyceraldehyde-3-phosphate dehydrogenase (PfGAPDH) (16,
44, 45) were used as loading controls. Pfs16 is a gametocyte stage-specific
protein (46), and GAPDH is a housekeeping protein present in P. falcip-
arum asexual blood stages and in gametocytes. Membranes were imaged
using an Odyssey infrared imaging system (LI-COR Biosciences).
Asexual stageP. falciparum in vitro growth inhibition assays.The in
vitro activity of compounds against asexual P. falciparum lines 3D7 and
Dd2 was determined using [3H]hypoxanthine incorporation (47, 48). Se-
rial dilutions of compounds were prepared in culture medium, and then
synchronous ring-stage-infected erythrocytes were added at 0.25% para-
sitemia and a 2.5% final hematocrit. Following 48 h of incubation,
[3H]hypoxanthine (0.5Ci/well) was added to each well and the cultures
were incubated for a further 24 h. Hypoxanthine incorporation into par-
asites was measured by harvesting onto 1450 MicroBeta filter mats (Wal-
lac) and counting using a 1450MicroBeta liquid scintillation counter. The
percent inhibition of growth compared to the growth of the matched
DMSO controls (0.5%) was determined. Each assay was carried out in
triplicate wells on three separate occasions. In each assay, chloroquinewas
included as an internal control. The 50% inhibitory concentrations
(IC50s) were determined using log-linear interpolation of inhibition
curves (49) and are presented as themeans standard deviations (SDs) of
the three independent assays.
In vitro mammalian cell toxicity assays. Cytotoxicity assays were
performed essentially as previously described (50). Briefly, neonatal fore-
skin fibroblasts (NFFs) were cultured in RPMI 1640 medium (Life Tech-
nologies) supplemented with 10% heat-inactivated fetal calf serum (CSL
Biosciences) and 1% penicillin-streptomycin (Life Technologies). Cells
were seeded into wells of 96-well tissue culture plates (3,000 cells per well)
and cultured for 24 h at 37°C in 5% CO2 before being treated with a
dilution series of each compound. After 72 h, medium was removed and
plates were washed in PBS. Cells were fixed with denatured alcohol before
a water wash and the addition of sulforhodamine B (0.4%; 50 l; Sigma-
Aldrich). After staining for 1 h, plates were washed three times with 1%
acetic acid, and then 100l of 10 mMTris base (unbuffered, pH9) was
added to each well. Plates were read at 564 nm in an enzyme-linked im-
munosorbent assaymicroplate reader. Percent inhibition of growth com-
pared to the growth of the matched DMSO controls (0.5%) was then
determined. Each assay was performed in triplicate on three separate oc-
casions, and chloroquinewas included as an internal control in each assay.
IC50s were determined using log-linear interpolation of inhibition curves
(49) and are presented as means SDs of the three independent assays.
Gametocyte ATP assay.Mature stage V gametocytes (method 1) were
harvested at days 10 to 12 relative to the start of induction (M1-d0) and
enriched by magnetic separation using MACS columns (Miltenyi Biotec)
(38). Testingwas performedusing cryopreserved and thawed gametocytes
essentially as previously described (51). Approximately 5,000 thawed ga-
metocytes were dispensed into the wells of a 96-well plate with test com-
pounds or controls to give a final volume of 100 l, and the plate was
incubated at 37°C for 24 or 48 h under standard culture conditions. Bac-
Titer-Glo reagents (G8231; Promega) were added to a final volume of 200
l, and the assay was read using a GloMax 96 microplate luminometer
with an integration constant of 0.5 s. Sample readouts were compared to
the control ATP expression levels, and the percent ATP production was
calculated. A nonparametric two-tailed Student’s t test was used for sta-
tistical analysis of the difference between the test compounds and the
controls. All compounds were dissolved in DMSO and tested in triplicate
on three separate occasions at a concentration of 5 M (0.5% DMSO).
The assay included a vehicle control of standard culture medium with
0.5%DMSO (no drug).Methylene blue (5M)was included as a positive
control.
MitoTracker Red CM-H2XRos late-stage gametocyte imaging-
based viability assay.Highly synchronous stage IV gametocytes (method
2) were produced from transgenic NF54 P. falciparum parasites express-
ing the gametocyte-specific protein Pfs16 fused to green fluorescent pro-
tein (NF54Pfs16-GFP) (42, 52). Gametocytes were harvested using MACS
columns (Miltenyi Biotec) on day 8 relative to the start of induction (M2-
d0) and added to 384-well imaging plates at 33,000 gametocytes per well.
After addition of test or control compounds, the cells were incubated for
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72 h at 37°C in 5% CO2, 5% O2, and 80% N2. MitoTracker Red
CM-H2XRos (Invitrogen) was then added to each well (0.07 g/ml) and
the cells were incubated for 12 to 18 h, as described above. Compound
vehicle alone (0.4% DMSO) and puromycin (5 M) were used as con-
trols. Gametocyte viability was evaluated on an Opera (PerkinElmer)
high-content screening system. The images acquired for GFP and Mito-
Tracker Red CM-H2XRos were overlaid, and the number of viable elon-
gated gametocytes per imagewas determined using an algorithmbased on
Acapella software developed for use with the Opera imaging system.
Compound data were normalized to the relative percent inhibition of the
controls (5 M puromycin and 0.4% DMSO). IC50 calculation was per-
formed using the GraphPad Prism program (version 4.0). Data were an-
alyzed using 4-parameter nonlinear regression (curve fit) with the sigmoi-
dal log dose-response (variable slope). Each compound was tested in
duplicate at 16 concentrations in at least two independent experiments. A
nonparametric two-tailed Student’s t test was used for statistical analysis
of the difference between the test compounds and the controls.
MitoTracker Red CM-H2XRos early-stage gametocyte imaging-
based viability assay. Highly synchronous early-stage gametocytes
were isolated (method 2) on day 2 relative to the start of induction
(M2-d0) using MACS columns and added to 384-well imaging plates
at 33,000 gametocytes per well. The remainder of the assay was con-
sistent with the MitoTracker Red CM-H2XRos late-stage gametocyte
imaging-based viability assay (42).
Assessment of gametocyte development via microscopy. Stage III
and IV gametocytes were seeded into tissue culture plates at 0.5%
gametocytemia and 5% hematocrit with test compounds (5M) or the
DMSO vehicle control (0.05%). Chloroquine was used as a negative
control. For microscopic evaluation of gametocytemia (number of
gametocytes per 100 erythrocytes), Giemsa-stained thin blood films
were examined via light microscopy. Approximately 3,000 to 4,000
cells were counted in each assay. Results of two independent experi-
ments were pooled, and data are presented as the mean percent game-
tocytemia  SD compared to that for the DMSO vehicle-treated con-
trol cultures (taken as 100%). A nonparametric two-tailed Student’s t
test was used for statistical analysis of the difference between the test
compounds and the controls.
P. falciparum exflagellation inhibition assay. Exflagellation assays
were carried out according to previously published methods (53–55). A
total volume of 100 l of mature NF54 gametocyte culture was preincu-
bated with SAHA and TSA at concentrations ranging from 0.125 to 2mM
and 0.06 to 0.5 mM, respectively, for 15 min at 37°C. Samples were then
transferred to room temperature, and xanthurenic acid was added at a
concentration of 100 M for activation. After 15 min, the number of
exflagellation centers in 30 optical fields was counted, in duplicate, using
a Leica DMLS microscope at 400-fold magnification. Two independent
experiments were performed for SAHA, and three independent experi-
ments were performed for TSA. The inhibition of exflagellation was cal-
culated as a percentage of the number of exflagellation centers in com-
pound-treated cultures in relation to the number for the untreated
controls (the value for untreated controls was set to 100%). TLCK at a
concentration of 30 M was used as a positive control. The IC50s were
calculated from variable-slope sigmoidal dose-response curves using the
GraphPad Prism program (version 5).
Ookinete conversion assay. Ookinete conversion assays were per-
formed using Plasmodium bergheiANKA parasites constitutively express-
ing GFP and followed existing protocols (56, 57), modified to utilize 48-
well culture plates. All inhibitors were dissolved in DMSO, and the results
were compared to those of the control treatmentswith 0.1%DMSOalone.
Fluorescent ookinetes were counted in duplicate for each experiment.
Hyperacetylation assay. Hyperacetylation assays were carried out by
incubating stage III and IV P. falciparum 3D7c gametocytes for 6 h under
standard in vitro culture conditions with different concentrations of test
compound or the vehicle control (0.05% DMSO). Protein lysates were
prepared as described above for asexual stage parasites. Briefly, cells were
harvested by centrifugation, lysed with 0.15% saponin (Sigma-Aldrich),
andwashed extensively using PBS (pH7.4) to remove hemoglobin. Pellets
were resuspended in 1 SDS-PAGE loading dye, heat denatured at 96°C
for 3min, and then separated via 15%SDS-PAGE. Proteinwas transferred
to a PVDF membrane (Roche), and Western blotting was carried out
using Odyssey blocking buffer (LI-COR Biosciences) according to the
manufacturer’s instructions. The following antisera were used to detect
acetylated histones: anti-tetra-acetylated H4 (lysines 5, 8, 12, and 16),
anti-acetylated H3 (N terminus), and anti-acetylated H3 (lysine 9) (Mil-
lipore). Antisera recognizing Pfs16 and PfGAPDH (44, 45) were used as
loading controls. Membranes were imaged using an Odyssey infrared im-
aging system (LI-COR Biosciences).
RESULTS
HDACs are expressed in P. falciparum gametocytes. The ge-
nome of P. falciparum encodes five HDAC proteins, termed
PfHDAC1 to PfHDAC3 (PlasmoDB gene accession numbers
PF3D7_0925700, PF3D7_1472200, and PF3D7_1008000, respec-
tively), PfSir2a (PlasmoDB gene accession number PF3D7_
1328800), and PfSir2b (PlasmoDB gene accession number
PF3D7_1451400). Previous transcriptomic and proteomic studies
have indicated that some PfHDACs are expressed in gametocyte-
stage parasites (12, 16), with PfHDAC1 shown by Northern blot-
ting to be transcribed in gametocytes (43). Here we used diagnos-
tic RT-PCR to confirm the transcription of all fiveHDACs in early
gametocytes (stage III), late gametocytes (stage V), and stage V
gametocytes following 30 min activation with 100 M xan-
thurenic acid (Fig. 1a). The stage specificity of the RNA samples
was confirmed by examining the transcription of the asexual
blood-stage-specific Pfama1 gene and the gametocyte-specific Pf-
ccp2 gene. Transcription of Pfaldo, which encodes the ubiquitous
plasmodial fructose-1,6-bisphosphate aldolase, was used as a
loading control. Samples lacking reverse transcriptase were used
to demonstrate that the RNA samples were devoid of genomic
DNA (Fig. 1a).
Next, the expression of PfHDAC1, a validated target of anti-
malarial HDAC inhibitors in asexual stage parasites (58), was con-
firmed in P. falciparum gametocytes by Western blotting and im-
munofluorescence assay using a polyclonal antiserum raised
against a C-terminal peptide (43) of PfHDAC1 (Fig. 1b and c). For
Western blotting, protein lysateswere prepared fromasexual stage
P. falciparum 3D7 trophozoites and 3D7c gametocytes (method 1)
on days 4, 6, 8, and 10 relative to the start of induction (M1-d0).
Microscopic examination of Giemsa-stained thin blood films
(Fig. 2a) showed that cultures harvested on day 4 contained
83.5%  3.5% gametocyte stages I to III, with 16.5% of par-
asites not being able to be distinguished from asexual stages.
On day 6, cultures were 95%  2.8% gametocytes (stages III
and IV), and on days 8 and 10, no asexual blood stages were
observed (100% gametocytes; stages IV and V). Two-color
Western blots showed a band of 50 kDa in all samples when
reacted with anti-PfHDAC1 rabbit antiserum; this corresponds
to the predicted size of PfHDAC1. As expected, an 16-kDa
band was present in induced gametocyte samples but not asex-
ual stage 3D7 parasite samples, using mouse antiserum specific
to the gametocyte marker protein Pfs16 (Fig. 1b). Immunoflu-
orescence assay data using anti-PfHDAC1 showed localization
primarily to the nucleus of late-stage gametocytes (Fig. 1c),
consistent with the asexual blood stage localization of this pro-
tein (43). Together these data confirm that PfHDAC1 is ex-
pressed in both asexual and gametocyte stages.
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Histone and nonhistone proteins are acetylated in different
gametocyte stages. The acetylation of histone and nonhistone
proteins was examined in gametocytes using Western blotting
with antisera that recognize tetra-acetylated histone H4 and pan-
acetylated lysine residues. A similar profile of tetra-acetylated his-
tone H4 reactivity was observed in P. falciparum 3D7c protein
lysates as gametocytes developed (Fig. 2b). As previously observed
for asexual blood-stage parasites (59), Western analysis using an-
tiserum that pan-specifically reacts with all acetylated lysine resi-
dues detectedmultiple protein bands spanning a widemass range.
The most strongly reactive band at60 kDa was found to alter as
parasites progressed from early- to late-stage gametocytes. The
acetylation of other proteins remained constant from days 4 to 10
relative to the start of induction (M1-d0), indicating that the re-
duced acetylation reactivity seen on days 6 and 8 using the pan-
acetyl lysine antiserum was not due to unequal loading.
Gametocytes are inhibited in vitro byHDAC inhibitor expo-
sure. To assess the susceptibility of gametocytes to chemical epi-
genetic modifiers, the effect of three commercially available
HDAC inhibitors was first examined. TSA and SAHA (Fig. 3) are
canonical paninhibitors that act on class I/II eukaryotic HDACs 1
to 9 with roughly equal potency (60) and have previously been
FIG 1 Expression of HDACs in P. falciparum gametocytes. (a) Diagnostic RT-PCR on transcripts from trophozoites (Troph) of gametocyte-less strain F12,
purified NF54 stage III and V gametocytes (Gam III and Gam V, respectively), and stage V gametocytes at 30 min postactivation (aGam V) with 100 M
xanthurenic acid at room temperature. RT-PCR was carried out with PfHDAC-specific primers. The expression levels of Pfama1 and Pfccp2 were used to verify
blood-stage and gametocyte-specific expression, respectively. Samples lacking reverse transcriptase (RT) were used as controls for genomic DNA contamina-
tion. The fructose-1,6-bisphosphate aldolase-encoding gene (Pfaldo) served as a loading control. All PCR products had nucleotide lengths of 200 to 300 bp. Lane
M, 100-bpmarker. (b)Western blot analysis of protein lysates from trophozoite-stage 3D7 P. falciparum parasites (asexual) and P. falciparum 3D7c gametocytes
(method 1) on days 4 (stages I to III), 6 (stages III and IV), 8 (stages IV and V), and 10 (stages IV and V) relative to the start of induction (M1-d0). Protein lysates
were analyzed by SDS-PAGE and two-color Western blot analysis using an Odyssey infrared imaging system (LI-COR Biosciences). The same membrane was
probed with anti-PfHDAC1 rabbit antiserum (red) and anti-Pfs16 mouse antiserum (green). (c) Immunofluorescence image of late-stage gametocytes showing
a bright-field image (top left), nuclear staining with DAPI (4=,6-diamidino-2-phenylindole; top right), predominantly nuclear localization with anti-PfHDAC1
antiserum (bottom left), and an overlay (bottom right).
FIG 2 Lysine acetylation during gametocyte development. (a) Samples were collected from P. falciparum 3D7c parasites (method 1) on days 4 (stages I to III),
6 (stages III and IV), 8 (stages IV and V), and 10 (stages IV and V) relative to the start of gametocyte induction (M1-d0). (b) Protein lysates were analyzed by
SDS-PAGE and two-colorWestern blot analysis using anOdyssey infrared imaging system (LI-CORBiosciences).Membranes were probed with anti-pan-acetyl
lysine (K103)mouse antiserumand anti-PfGAPDHrabbit antiserumor anti-tetra-acetylated (lysines 5, 8, 12, and 16) histoneH4 rabbit antiserumand anti-Pfs16
mouse antiserum. Arrow, an60-kDa protein showing altered acetylation during gametocyte development. p.i., postinduction.
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shown to have potent inhibitory activity against asexual blood-stage
P. falciparum parasites (Table 1) (61–63). The third HDAC inhib-
itor tested, CAY10603 (Fig. 3), while also having a hydroxamate
zinc-binding group like TSA and SAHA, demonstrates some iso-
form selectivity for human HDAC6 (64). When we tested the ac-
tivity of this compound against asexual stage P. falciparum para-
sites (Table 1), we observed a level of inhibitory activity similar to
that of SAHA against P. falciparum drug-sensitive (3D7 line; IC50,
0.17 M) and drug-resistant (Dd2 line; IC50, 0.34 M) parasites.
To determine whether SAHA, TSA, and CAY10603 had activ-
ity against sexual stage malaria parasites, the compounds were
tested against late-stage gametocytes using two previously pub-
lished assays: an ATP production assay using 3D7c gametocytes
(51) and an imaging-based viability assay that utilizes transgenic
NF54 parasites expressing Pfs16 fused to the GFP reporter
(NF54Pfs16-GFP) combined with MitoTracker Red CM-H2XRos
staining (42). In each assay, methylene blue, which is a potent
inhibitor of gametocyte development across all stages (52), was
used as a positive control. The data demonstrate that exposure to
5 M SAHA, CAY10603, or methylene blue for 48 h (Fig. 4a)
significantly reduced gametocyte ATP activity (P  0.001). Al-
though there was a trend toward reduced ATP production in the
presence of TSA, this effect was not statistically significant (P 
0.05). In contrast, the imaging-based viability assay showed a sig-
nificant reduction (P  0.001) in gametocyte viability for TSA,
SAHA, and methylene blue, but not CAY10603 (Fig. 4b). To con-
firm these findings, microscopy was also used to monitor the
HDAC inhibitor effect on P. falciparum gametocytes. All three
HDAC inhibitors, but not the control compound, chloroquine,
were found to significantly inhibit the growth/maturation of stage
III and IV 3D7c gametocytes after 5 days of exposure (Fig. 4c
and d).
Gametocytocidal activity of novel HDAC inhibitor ana-
logues.Tobegin to assess the potential ofHDAC inhibitors as new
FIG 3 Structures of the HDAC inhibitors used in this study.
TABLE 1 In vitro antimalarial activity of HDAC inhibitors against asexual and gametocyte-stage P. falciparum parasites
Compound
IC50 (M)
Selectivity indexc
Asexual stagea Gametocyteb
NFFs3D7 Dd2 Early stage Late stage
TSA 0.01d 0.008e 0.09 0.01 0.07 0.02 0.2d 18–25 (3)
SAHA 0.12 0.04e 0.19 0.01e 1.41 0.13 0.81 0.21 4.90 1.24 26–41 (6)
CAY10603 0.17 0.03 0.34 0.29 4.00 4.00 4.04 0.74 12–24 (1)
1 0.25 0.07 0.32 0.10 2.25 0.67 2.12 0.44 19.5 3.8 36–78 (9)
2 0.45 0.05 0.54 0.31 6.65 1.04 1.68 0.33 11.4 0.2 21–25 (2–7)
3 0.82 0.09 1.32 0.01 14.60 2.36 3.20 1.92 33.2 9.1 25–40 (2–10)
4 1.09 0.27 1.17 0.16 10.00 3.57 0.29 37.1 0.2 32–34 (3–10)
5 1.42 0.60 3.13 0.33 10.00 9.15 3.11 79.9 12.0 26–56 (8–9)
MBf NDg ND 0.24 0.02 0.23 0.02 ND ND
CQh 0.01 0.003 0.13 0.02 0.20 0.02 120.00 21.4 3.1 164–2,140 (1)
a Results are the means of three independent in vitro [3H]hypoxanthine growth inhibition assays, each of which was carried out in triplicate.
b Results are means SDs of 2 to 4 MitoTracker Red CM-H2XRos gametocyte image-based viability experiments, each of which was carried out in duplicate.
c Selectivity indices are for asexual stage parasites and late-stage gametocytes (in parentheses) and were calculated as the mammalian cell IC50/P. falciparum IC50; larger values
indicate greater parasite selectivity.
d Data previously reported (61, 76).
e Data previously reported (73).
f MB, methylene blue.
g ND, not determined.
h CQ, chloroquine.
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agents for blocking the transmission of gametocytes to the mos-
quito, we used the MitoTracker Red CM-H2XRos imaging-based
viability assay to compare the early- and late-stage gametocyto-
cidal activity of TSA, SAHA, and CAY10603 with that of a panel of
five other HDAC inhibitors (compounds 1 to 5; Fig. 3). The
alkoxyurea compounds (compounds 1 and 2) were previously
identified to be potent human pan-HDAC inhibitors (65). The
phosphonic ester (compound 3), the alkoxysemicarbazide (com-
pound 4), and the amidoxime derivative (compound 5) have
not been described or tested before. The MitoTracker Red
CM-H2XRos imaging-based viability assaywas selected because of
the longer time of exposure to compounds (which ensures that the
activities of slower-acting compounds are also captured), and in
addition, it utilizes fresh versus cryopreserved gametocytes,
thereby bypassing the liabilities associated with the freeze-thaw
process. This assay also alloweddirect comparisons between early-
and late-stage gametocyte viability, as recently validated for high-
throughput applications (10, 42).
As compounds 1 to 5 had not previously been tested for activity
against asexual stage parasites, all five were first tested against
chloroquine-sensitive and -resistant asexual stage P. falciparum
parasites using the in vitro [3H]hypoxanthine growth inhibition
assay. Cytotoxicity against a normal human cell line was assessed
using the sulforhodamine B in vitro cell toxicity assay (Table 1).
Compounds 1 to 5 had asexual blood-stage activities with IC50s
ranging from 0.25 to 1.42 M. The most active compounds were
alkoxyurea compounds 1 (IC50, 0.25 M) and 2 (IC50, 0.45 M),
while the alkoxysemicarbazide (compound 4; IC50, 1.09 M) and
the amidoxime derivative (compound 5; IC50, 1.42M)displayed
considerably less potent inhibitory activity against the asexual
blood stage in vitro. All compounds of this series were less active
than the reference compounds, TSA and SAHA. The ability of one
of the more potent compounds (Table 1, compound 1) to cause
hyperacetylation of asexual blood-stageP. falciparumhistoneswas
demonstrated using trophozoite-stage parasites (see Fig. S1 in the
supplemental material), confirming an effect on P. falciparum
HDAC activity in asexual stage parasites. Comparison of the IC50s
for asexual blood-stage P. falciparum with those obtained for the
normal NFF mammalian cell line shows that members of this
panel of HDAC inhibitors have somewhat better selectivities (se-
lectivity indices, 21 to 78) than SAHA or TSA (selectivity indices,
18 to 41) (Table 1).
When evaluated against early- and late-stage NF54Pfs16-GFP ga-
metocytes, TSA was found to be the most potent compound, with
IC50s of 0.09 and 0.07M, respectively (Table 1). This activity was
better than that observed for the control compound, methylene
blue (IC50, ~0.2 M; Table 1). SAHA had less potent activity
against early- and late-stage gametocytes, with IC50s of 1.4 and 0.8
FIG 4 Activity of TSA, SAHA, and CAY10603 against gametocytes. (a) ATP activity assay with cryopreserved and thawed MACS-purified stage V 3D7c
gametocytes following 48 h of exposure to 10Mmethylene blue (MB) or 5MTSA, SAHA, or CAY10603. Controls contained vehicle only (0.5%DMSO). The
mean percent ATP production  SD is shown for three independent experiments, each of which was carried out in triplicate wells (**, P  0.001). (b)
MitoTracker Red CM-H2XRos imaging-based viability assay with stage IV and VNF45
Pfs16-GFP gametocytes. Cells were incubated for 72 h with 4Mmethylene
blue, TSA, SAHA, or CAY10603 and then incubated for 16 h with MitoTracker Red CM-H2XRos (and compound) before imaging. Controls contained vehicle
only (0.5%DMSO). Themean percent growth SD is shown for two independent experiments, each of which was carried out in duplicate wells (**, P 0.001).
(c and d) Stage III and IV gametocytes (0.5% gametocytemia, 5% hematocrit) were cultured with 5 M TSA, SAHA, CAY10603, or the antimalarial drug
chloroquine (CQ) for 2 days (c) or 5 days (d), with medium (without compound) being changed on day 2. Control cultures were incubated in the same way but
contained vehicle only (0.05% DMSO). Thin blood films were prepared and stained with Giemsa, and the number of gametocytes per 100 cells (percent
gametocytemia) was determined by microscopy (3,000 cells were counted). The mean percent gametocytemia SD compared to that for the vehicle controls
(taken as 100%) from two independent experiments is shown (**, P 0.001).
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M, respectively, while CAY10603 had an IC50 of4 M against
both stages (Table 1). All five new HDAC inhibitor analogues
displayed only modest gametocytocidal activity, with IC50s rang-
ing from 1.7 to 10 M. As for the asexual stages, alkoxyurea
compounds 1 and 2 showed the most potent inhibitory activity.
The selectivity of these compounds for gametocytes versus mam-
malian cells was similar to that of TSA and SAHA (selectivity in-
dices, 2 to 10; Table 1).
HDAC inhibitors are not effective in inhibiting gametocyte
exflagellation. To assess the effect of HDAC inhibitors on male
gamete formation, we carried out in vitro exflagellation exper-
iments using mature P. falciparum NF54 gametocytes. During
this process, exflagellatingmale gametes attach to nearby erythro-
cytes, thereby forming exflagellation centers, which can easily be
observed under a microscope. Both SAHA and TSA inhibited ex-
flagellation, but low-mM concentrations were required (SAHA
IC50, 0.50 0.003 mM; TSA IC50, 0.22 0.04 mM; see Fig. S2 in
the supplemental material). Tosyllysine chloromethyl ketone hy-
drochloride (TLCK), an inhibitor of trypsin-like serine proteases,
was used as a positive control. TLCK was previously shown to
effectively inhibit exflagellation (53, 54), and at a concentration of
30 M, it fully blocked the formation of exflagellation centers.
A similar finding was also observed for the in vitro conversion
of P. bergheimousemalaria gametocytes to ookinetes in vitro. This
assay is a relatively robust predictor of transmission blocking in
the insect stages of the parasite life cycle (66), providing informa-
tion about the effects of compounds on gamete formation, fertil-
ization, and ookinete formation. Treatment with SAHA at con-
centrations up to 25 M had no effect on ookinete conversion.
Similarly, TSA at 5 M and CAY10603 at 2.5 Mwere not inhib-
itory. In contrast, 1 M cycloheximide completely inhibited oo-
kinete formation. This suggests that HDAC inhibitors of this class
have little impact on the sexual reproduction and transformation
of the zygote to ookinete stages.
HDAC inhibitors cause hyperacetylation of P. falciparum
gametocyte histone proteins. To determine whether HDAC in-
hibitors alter the lysine acetylation profile of proteins in gameto-
cyte stages, hyperacetylation assays were carried out. Mixed stage
III and IV gametocyteswere treated for 6 hwith 5MTSA, SAHA,
CAY10603, or the control compound methylene blue or chloro-
quine. Protein lysates were analyzed by Western blotting using
antisera specific for acetylated forms of histones H3 and H4 (Fig.
5) or using pan-acetyl lysine antiserum (see Fig. S3 in the supple-
mental material). In comparison to the vehicle control (0.05%
DMSO)-, methylene blue-, or chloroquine-treated parasites, hy-
peracetylation was observed for all three HDAC inhibitors using
antisera to tetra-acetylated H4 (lysines 5, 8, 12, and 16), N-termi-
nally acetylated H3, and lysine 9-acetylated H3 (Fig. 5). In con-
trast, HDAC inhibitor treatment did not appear to alter the acet-
ylation profilewhennonhistone proteinswere examinedusing the
pan-acetyl lysine antiserum (see File S3 in the supplemental ma-
terial).
DISCUSSION
The eradication of malaria will require a multipronged approach,
including the development of new therapies that block the trans-
mission ofmalaria parasites from the human host to themosquito
vector (67). A major bottleneck in developing such transmission-
blocking agents is our relatively poor understanding of how sexual
stage malaria parasites develop within the host erythrocyte and
which enzymes and proteins are essential for this process. Recent
progress toward the in vitro production of large-scale, pure, game-
tocyte cultures (68) has now opened up new opportunities to im-
prove our understanding of gametocyte biology and use this in-
formation to develop new drugs that target this malaria parasite
life cycle stage. In this study, we examined lysine acetylation as a
potential new therapeutic target for gametocytes.We confirm that
at least one P. falciparum histone deacetylase (PfHDAC) protein is
expressed in gametocytes, that histone and nonhistone protein
acetylation occurs in this life cycle stage, and that small molecules
of theHDAC inhibitor classmay be novel leads for blocking trans-
mission of sexual stage malaria parasites to the mosquito vector.
HDACs, enzymes involved in regulating lysine acetylation of
histone and nonhistone proteins in eukaryotic cells, are a recog-
nized drug target in asexual stage malaria parasites (30, 58, 69).
Five HDAC-encoding genes have been identified in the P. falcip-
arum genome (70). While the two class III HDAC homologues,
PfSir2a (PlasmoDB gene accession number PF3D7_1328800) and
PfSir2b (PlasmoDB gene accession number PF3D7_1451400), are
not essential to asexual stage P. falciparum survival in vitro (71,
72), the three class I and II HDAC homologues, PfHDAC1 to
PfHDAC3 (PlasmoDB gene accession numbers PF3D7_0925700,
PF3D7_1472200, and PF3D7_1008000, respectively), are poten-
tial targets of antimalarial HDAC inhibitors.PfHDAC1has50%
homology to other mammalian HDACs (43), and a recombinant
form of this protein can be potently inhibited by antimalarial
HDAC inhibitors like TSA and SAHA (58). In contrast, PfHDAC2
and PfHDAC3 share very little sequence homology with any
mammalian HDACs and have not been characterized. Despite
work demonstrating the potential of HDAC inhibitors against
asexual P. falciparum parasites (recently reviewed in reference 30)
and transcriptomic and proteomic data showing that PfHDACs
are expressed in both asexual stage and gametocyte-stage P. falcip-
arum parasites (12, 15, 18, 43), this class of important transcrip-
tional regulators has not previously been studied in gametocytes
FIG 5 HDAC inhibitors cause hyperacetylation of gametocyte histones. Stage
III and IV P. falciparum 3D7c gametocytes were treated with 5 Mmethylene
blue (MB), chloroquine (CQ), TSA, SAHA, CAY10603, or vehicle only (0.05%
DMSO as a control [C]) for 6 h. Protein lysates were analyzed by SDS-PAGE
and Western blotting using antisera recognizing acetylated forms of histone
H3 and H4: anti-tetra-acetylated H4 (lysines 5, 8, 12, and 16), anti-acetylated
H3 (N terminus [N-term]), and anti-acetylated H3 (lysine 9 [lys 9]). Antisera
recognizing Pfs16 and PfGAPDH were used as loading controls.
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or investigated as a target for blocking malaria parasite transmis-
sion.
Previous work from our group and others using antisera that
specifically recognize acetylated forms of proteins has shown that
both histone and nonhistone proteins are acetylated in asexual
stage P. falciparum parasites (59, 73).Whenwe used this approach
to examine protein acetylation during gametocyte development,
we found that while the tetra-acetylated H4 profile was similar in
all developmental stages as gametocytes matured, the panacety-
lated lysine profile was altered. An 60-kDa acetylated protein
species was apparent in some, but not all, developmental stages.
While this raises the intriguing possibility that this protein may
play a role in gametocyte development, further work will be
needed to identify this protein and characterize its precise role
during the gametocyte life cycle. Likewise, our data showing his-
tone H4 tetra-acetylation in all the development stages examined
provides only a snapshot of histone acetylation in gametocytes.
Further analysis of different acetylated forms of H4 and other
histones is needed to improve our understanding of the role of
lysine acetylation during gametocyte development.
Given that our data showed that lysine acetylation occurs in
gametocytes (Fig. 2) and confirmation that at least one PfHDAC is
expressed in this life cycle stage (Fig. 1), we next examined the
gametocytocidal activity of three commercially available HDAC
inhibitors (TSA, SAHA, andCAY10603) using different published
assays: an ATP metabolic assay, an imaging-based viability assay,
and assessment via microscopy (Fig. 4). Overall, the three meth-
ods gave a similar trend, with all three HDAC inhibitors demon-
strating some gametocytocidal activity, although there were vari-
ations in the levels of inhibition obtained. While it is not possible
to directly compare the data obtained for the different assaymeth-
ods, given that factors such as variations in gametocyte induction
and purification protocols for the different assays, stage- and sex-
specific ratio differences, variations in the length of each assay, and
different endpoint detection methods preclude this, we were able
to illustrate a general trend. Each of these factors would have con-
tributed to variations in compound efficacy, as has been previ-
ously noted (reviewed in reference 68). Differences in the results
of theATPmetabolic assay and theMitoTracker RedCM-H2XRos
imaging-based viability assay are most likely due to not only those
factors highlighted above but also the differences in starting ga-
metocyte stage (mature stage V versus stages IV and V, respec-
tively), duration of compound exposure (48 h of exposure versus
96 h of exposure, respectively), and the use of cryopreserved ga-
metocytes in the ATP assay versus fresh gametocytes in the imag-
ing-based assay. While the results for TSA and SAHA were gener-
ally consistent, the activity of CAY10603wasmore variable. Itmay
be that this compound has a steep dose-response curve that im-
pacts activity at this concentration; however, concentrations
higher than 5 M were not examined in this study.
On the basis of the results of initial studies with the three com-
mercial HDAC inhibitors, the MitoTracker Red CM-H2XRos im-
aging-based viability assay was selected to further examine the
activity of these and other HDAC inhibitors (10, 42). A panel of
five structurally diverseHDAC inhibitors containing different cap
groups and connecting-unit linker regions was assessed. As none
of these compounds had previously been tested against asexual
stage parasites, we first determined their asexual stage IC50s
against a drug-sensitive line (3D7) and a drug-resistant line (Dd2)
of P. falciparum. While none of the compounds were as potent as
TSA or SAHA, they all had selectivity for asexual stage parasites
versus a normal mammalian cell line equivalent to or better than
that of those two reference compounds. Some asexual stage struc-
ture-activity relationship data were apparent, with the alkoxyurea
compounds 1 (IC50, 0.25M) and 2 (IC50, 0.45M) havingmore
potent asexual stage activity than the alkoxysemicarbazide (com-
pound 4; IC50, 1.09 M) and the amidoxime derivative (com-
pound 5; IC50, 1.42 M). In contrast to data obtained for asexual
stage parasites, none of the alkoxyurea compounds potently in-
hibited early- or late-stage gametocyte development (Table 1;
IC50s, 1.7 to10 M). Overall, the most potent gametocytocidal
HDAC inhibitor was TSA, which had similar potency against both
early- and late-stage gametocytes (Table 1; IC50s, 0.09 and 0.07
M, respectively) and better activity than the control compound,
methylene blue. Generally, the selectivity of the HDAC inhibitors
for gametocytes versus a normal mammalian cell was lower than
that for asexual stages and similar to that of the reference com-
pounds TSA and SAHA. These data demonstrate that while some
HDAC inhibitors have promising gametocytocidal activity, rais-
ing the possibility of development of this class of compounds as
new gametocytocidals in the future, improvements in both po-
tency and gametocyte-specific selectivity are still required.
It is widely accepted that late-stage gametocyte activity equal to
or better than that of asexual stage activity is essential for potential
transmission-blocking drugs. Our data show that the in vitro ga-
metocytocidal activities of the HDAC inhibitors examined in this
study are generally less than their activities against asexual stage
parasites (Table 1). Lower activity against gametocytes than asex-
ual stages is not unique to our study (42), with possible explana-
tions including variations in the expression of target proteins, al-
terations in compound uptake in the different life cycle stages, and
the technical limitations of current assays. For example, recent in
vitro work has shown that mature male gametocytes are more
sensitive to some antimalarial compounds than female gameto-
cytes (74). Given that gametocyte populations are dimorphic and
female biased (3 to 5 female gametocytes to 1male gametocyte),
future studies on this class of compounds will need to include
assessments of sex-specific effects. An improved understanding of
the target(s) of HDAC inhibitors in gametocytes may also help
improve the profiles of these compounds, for example, through
the targeting of particular HDAC isoforms. Other considerations
that will need to be addressed include gametocyte viability effects
versus developmental delay effects and the need for compounds
that have appropriate pharmacokinetic profiles and compatibility
with potential partner drugs.
In addition to killing early/late-stage gametocytes, down-
stream processes such as gamete formation in the mosquito may
be targets of transmission-blocking agents. When we assessed the
effect of the HDAC inhibitors SAHA and TSA on in vitro male
gamete formation, we observed very low inhibitory activity (IC50s,
200 to 500 M). Although the exflagellation inhibition activity of
compounds is generally markedly lower than that obtained
against mature gametocytes (53, 74), the exflagellation IC50s of
SAHA and TSA were at least 600-fold higher than the late-stage
gametocyte IC50s (Table 1). Likewise, no activity against the in
vitro conversion of P. berghei mouse malaria gametocytes to oo-
kinetes was observed. Althoughwe cannot preclude the possibility
of more potent inhibitory activity by the use of longer exposure
times, different classes of HDAC inhibitors, or inhibitors that tar-
get different isoforms in the parasite, our data indicate that the
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hydroxamate-based HDAC inhibitors SAHA and TSA have very
poor exflagellation and ookinete conversion inhibition activity.
While transmission-blocking studies were not performed in this
study, future work should also include transmission-blocking
studies in mosquitoes infected with HDAC inhibitor-treated ga-
metocytes.
Several HDAC inhibitors that are potent inhibitors of asexual
blood-stage P. falciparum parasites, including SAHA and TSA,
have been shown to inhibit recombinant PfHDAC1 in in vitro
enzyme assays (58). We and others have also demonstrated that
hyperacetylation of parasite histone and nonhistone proteins and
global transcriptional alterations are a functional consequence of
HDAC inhibitor exposure in asexual stage parasites (31, 32, 58, 63,
69, 73, 75). This is consistent with a mode of action of this class of
compounds that targets HDAC enzymes. When we examined the
effect of three HDAC inhibitors with various gametocytocidal ac-
tivities, TSA, SAHA, andCAY10603, on P. falciparum stage III and
IV gametocytes, we observed increases in histoneH3 andH4 acet-
ylation profiles (Fig. 5). While these data provide evidence of a
mode of action in targeting histone acetylation in gametocytes, it
is not possible to directly correlate gametocytocidal activity with
hyperacetylation data. To quantitate these changes, future studies
will need to consider differences in the physiochemical properties
of compounds (e.g., variations in log P [octanol-water partition
coefficient]), compound potency, timing and speed of action, and
variations in molecular targets, as well as profile the effect of these
and other compounds on different acetylated histone forms (e.g.,
tetra-acetylated H4 versus monoacetylated forms). Unfortu-
nately, many of the tools needed for such profiling are not cur-
rently available, in particular, recombinant forms of different P.
falciparum HDAC proteins. Future work should also focus on
determining whether the effect of HDAC inhibitors on gameto-
cytes is due to direct targeting of HDAC action or indirect effects.
Such profiling should include assessment of global transcriptional
and acetylomic changes in treated versus untreated parasites. In
contrast to the observed alteration to histone acetylation, nonhis-
tone acetylation did not appear to be affected under the conditions
utilized (see File S3 in the supplemental material). While this may
mean that nonhistone protein acetylation is not a target of these
HDAC inhibitors in gametocytes, additional workwill be required
to explore these apparent differences in more detail, including
comparison of the effects on different developmental forms and
on male versus female gametocytes and assessment of temporal
responses and the effect of additional compounds.
The importance of lysine acetylation in Plasmodium growth
and development has recently been highlighted by the identifica-
tion of the first acetylome of P. falciparum parasites. A total of 421
acetylation sites in 230 proteins were identified in asexual stage
parasites (59), with a significant divergence from those in other
eukaryotes being noted. Not only were a large number of Plasmo-
dium-specific proteins acetylated, but also different acetylation
sites were identified in evolutionarily conserved acetylated pro-
teins. This work, together with our findings, paves the way for
similar acetylomic studies in Plasmodium gametocytes. Our work
also identifies gametocytocidal HDAC inhibitors, such as TSA, to
be potentially useful tools for dissecting the roles of HDACs in
gametocyte development and on epigenetic regulation in this life
cycle stage.
Our data show that HDAC inhibitors are a novel starting point
for the development of new inhibitors of not only asexual (30) and
exoerythrocytic (73) stage parasites but also gametocytes. Safe and
effective antigametocyte drugs are crucial to any effort to eradicate
malaria because of the persistence of gametocytes in patients who
have been successfully treated for the disease. There are fewknown
inhibitors of this life stage, and the only approved drug, prima-
quine, has significant safety concerns. Because HDAC inhibitors
are also effective against asexual and exoerythrocytic parasite
stages (30, 73), development of a suitable drug candidate for use in
combination therapies to reduce gametocyte formation could
avoid many of the ethical issues associated with gametocyte-spe-
cific drugs. HDAC inhibition, either directly or indirectly via tar-
geting of essential coregulatory proteins unique to the Plasmo-
dium parasite, thus presents a promising strategy for the
development of novel antimalarial treatments.
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